EXECUTIVE SUMMARY

Full Year 2023

Main figures €Mn

Op. Revenue	EBITDA	EBIT
829.5 (+1%)	244.5 (-12%)	220.1 (-14%)
Net profit	**Capex**	**Net debt**
170.3 (-15%)	55.2 (+7%)	38.6

2024 operating revenue guidance:
Decrease by a mid-single-digit percentage vs 2023

- ✓ FDA approved the active substance manufacturing plan and CDMO's injectable plants for the manufacture of Moderna's COVID-19 mRNA vaccine.
- ✓ On 21 September 2023, ROVI received the Establishment Inspection Report from the FDA from the inspection of the facility. The FDA has established a new Goal Date, the 29 March 2024.
- ✓ First place in the Sustainalytics world ESG risk ranking for the second year running.

Operating revenue €Mn



Specialty pharma business €Mn

YoY

Total €420.2m

+1%



€373.5	0%	Prescription products
€45.7	+14%	Contrast agents
€1.0	-29%	Other

Heparin franchise* 30% of operating revenue — €250.6m — -5%

LMWH — €242.1m — -6%

Enoxaparin sales — €147.9m — -3%

- ✓ Directly marketed in Germany, UK, Italy, France, Belgium, Portugal, Spain, Poland and Austria.
- ✓ Approved in 26 countries in Europe and 33 in RoW.
- ✓ Launched in 40 countries.

* LMWH (Bemiparin and Enoxaparin biosimilar) + other heparins

Other prescription-based pharmaceutical products

Neparvis® — €45.5m — +16%

Orvatez® — €26.5m — +8%

Okedi® — €14.4m

- ✓ Lead candidate Risperidone ISM®, a LAI of risperidone for schizophrenia.
- ✓ Approved for commercialization in Europe in Feb 2022 (launched in Germany, UK, Spain, Portugal, Italy, Austria, Serbia and Greece) and in approval process in U.S.

CDMO[(1)] business €Mn

Total €409.3m

+1%

[(1)]Contract Development and Manufacturing Organisation

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 35-39) of the press release on the financial results for the full year 2023. Said document is available on ROVI's website and may be accessed on the following link https://www.rovi.es/en/shareholders-investors/financial-business-information

Gross profit €Mn



SG&A expenses €Mn



EBITDA €Mn



EBITDA Pre-R&D[1] €Mn **€269.4m** **-11%**

R&D expenses €Mn €24.9 +4%

Product	Potential Indication	Current Situation	Key Milestones
Okedi® Risperidone, monthly	**Schizophrenia**	Approved	Approved in Europe and in approval process in USA
Letrozole ISM®, annual	**Breast Cancer**	Clinical development on hold	Phase I: Superior oestrogen suppression vs Femara®
Letrozole LEBE, quarterly	**Breast Cancer**	Phase I	
Risperidone, quarterly	**Schizophrenia**	Phase I	

Concentrated on improving posology for already approved compounds, which benefits risk / reward profile

Multiple FDA / GMP approved facilities to support the platform

Net profit €Mn



Net profit Pre-R&D[1] €Mn **€189.6m** **-13%**

(1) Calculated excluding R&D expenses in 2023 and 2022

To obtain further information on the alternative performance measures (APMs) and non-IFRS financial indicators used, including the definition thereof and a reconciliation between the applicable management indicators and the financial information set out in the consolidated financial statements prepared under IFRSs, please consult the information included on this subject on page 1 and Appendix 2 (pages 35-39) of the press release on the financial results for the full year 2023. Said document is available on ROVI's website and may be accessed on the following link https://www.rovi.es/en/shareholders-investors/financial-business-information

News flow

SPECIALTY PHARMA

- ✓ Sales of enoxaparin biosimilar
- ✓ New product distribution licenses
- ✓ Granting by the competent local authorities of the marketing authorization of an Enoxaparin biosimilar outside Europe

CDMO

- ✓ Evolution of Moderna's vaccine manufacturing.

ISM® Technology Platform

- ✓ Launch of Okedi® in Europe (already launched in Germany, UK, Spain, Portugal, Italy, Austria, Greece and Serbia)
- ✓ Marketing authorization for Risvan® in USA
- ✓ Phase I clinical development of a three-monthly formulation of letrozole (Letrozole LEBE)
- ✓ Phase I clinical development of Risperidone for a 3-monthly injection